Dianthus Therapeutics (DNTH) Equity Average (2018 - 2025)

Dianthus Therapeutics has reported Equity Average for 8 years, with the latest figure at $519.9 million in Q4 2025.

• For the quarter ending Q4 2025, Equity Average rose 50.62% year-over-year to $519.9 million; the trailing twelve-month figure through Dec 2025 stood at $519.9 million (up 50.62% YoY), and the FY2025 full-year result was $422.9 million, up 62.25% from the prior year.
• Equity Average for Q4 2025 stood at $519.9 million, up from $424.8 million in the prior quarter.
• The five-year high for Equity Average was $519.9 million in Q4 2025, with the low at -$56.1 million in Q2 2023.
• Average Equity Average over 5 years is $176.4 million, with a median of $169.8 million recorded in 2021.
• Year-over-year, Equity Average tumbled 145.88% in 2022 and jumped 750.97% in 2024.
• Tracing DNTH's Equity Average over 5 years: stood at $86.2 million in 2021, then plunged by 145.88% to -$39.6 million in 2022, then soared by 538.88% to $173.6 million in 2023, then soared by 98.81% to $345.2 million in 2024, then surged by 50.62% to $519.9 million in 2025.
• The last three Equity Average figures came in at $519.9 million (Q4 2025), $424.8 million (Q3 2025), and $315.8 million (Q2 2025), per Business Quant data.

Peer Comparison